Idiotype vaccination strategies in myeloma: How to overcome a dysfunctional immune system

Clinical Cancer Research

Volumn 13, Issue 5, 2007, Pages 1353-1355

  Van Rhee, Frits ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG HYPERSENSITIVITY; HUMAN; IMMUNOPATHOLOGY; LYMPHOMA; MONOCLONAL IMMUNOGLOBULINEMIA; MONOTHERAPY; MYELOMA; NOTE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; MULTIPLE MYELOMA; T-LYMPHOCYTES;

EID: 33947411996     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2650     Document Type: Note

References (38)

1. Hansson L, Abdalla AO, Mosfegh A, et al. Long-term idiotype vaccination combined with IL-12, or IL-12 and GM-CSF, in early stage multiple myeloma patients. Clin Cancer Res 2007;13:1503-10.
2. Daley MJ, Gebel HM, Lynch RG, et al. Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy. J Immunol 1978;120: 1620-4.
3. Faberberg J, Yi Q, Gigliotti D, et al. T cell epitope mapping of the idiotypic monoclonal IgG heavy and light chain in multiple myeloma. Int J Cancer 1997; 80:671-80.
4. Hansson L, Rabbani H, Fagerberg J, et al. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 2003; 101:4930-6.
5. Wen YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T-lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001;97:1750-5.
6. Yi Q, Osterborg A, Bergenbrant, et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995;86:3043-9.
7. Osterborg A, Yi Q, Bergenbrant S, et al. Idiotype-specific T cells in multiple myeloma stage I: and evaluation by four different functional tests. Br J Haematol 1995;89:110-6.
8. Lauritzsen GF, Weiss S, Dembic Z, et al. Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A 1994;91:5700-4.
9. Yi Q. Dendritic cell based immunotherapy in multiple myeloma. Leuk Lymphoma 2003;44:2031-8.
10. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high dose chemotherapy. Blood 1999;94:673-83.
11. Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage-colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998;91:2459-66.
12. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood 1997;89:3129-35.
13. Bendandi M, Gocke CD, Korbin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-7.
14. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999;77:2411-9.
15. Jonuleit H. Schmitt E. Schuler G, et al. Induction of interleukin 10-producing, non-proliferating CD4 (+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192:1213-22.
16. Fiore F, Nuschak B, Peola S, et al. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of TRI-like regulatory T cells. Eur J Immunol 2005;35:1155-63.
17. 1 and interleukin-10. Blood 2001;98:2992-8.
18. Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002;100:230-7.
19. Brown R, Murray A, Pope B, et al. Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor B in patients with myeloma. Br J Haematol 2004;125:746-8.
20. 2-Microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 2003;101:4005-12.
21. Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006;203:1859-65.
22. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
23. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cell following therapeutic cancer vaccines. Blood 2006;107:62-36.
24. + regulatory T cells in patients with multiple myeloma. Blood 2006; 106:3940-9.
25. high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006;108: 2655-61.
26. Onizuka S, Tawara I, Shimiza J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 1999; 59:3128-33.
27. Rao PE, Petrone AL, Ponath PD, et al. Differentiation and expansion of T Cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-β. J Immunol 2005;174:1446-55.
28. Lee P, Wong F, Rubio KV, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001; 19:3836-47.
29. Bianchi R, Grohmann U, Vacca C, et al. Autocrine IL-12 is involved in dendritic cell modulation via CD40 ligation. J Immunol 1999;163:2517-21.
30. - dendritic cells to enhance presentation of a tumor peptide in vivo. J Immunol 1999;163:3100-5.
31. Fenghuang Z, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108: 2020-8.
32. hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018-25.
33. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8.
34. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 5:1471-90.
35. Laurenti L, Piccioni P, Piccirillo N, et al. Immune recovery of lymphocyte subsets 6 years after autologous peripheral blood stem cell transplantation (PBSCT) for lymphoproliferative diseases. A comparison between NHL, HD and MM in group of 149 patients. Leuk Lymphoma 2004;4:2063-70.
36. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of underdetermined significance. Blood 2005;106:812-7.
37. Wang S, Hong S, Yang J, et al. Optimizing immunotherapy in multiple myeloma: restoring the function of patient's monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in the progenitor cells. Blood 2006;108:4071-7.
38. Shevach EM. Fatal attraction: tumors beckon regulatory T cells. Nat Med 2004;10:900-1.